April 21, 2023 FDA authorizes changes to simplify use of bivalent mRNA COVID-19 vaccines Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals.
Aug. 31, 2022 FDA authorizes Moderna, Pfizer-BioNTech bivalent COVID-19 vaccines for use as a booster dose The U.S. Food and Drug Administration amended the emergency use authorizations of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of the vaccines for use as a single booster dose at least two months following primary or booster vaccination.
Jan. 6, 2021 Air Force Surgeon General visits Joint Base Anacostia-Bolling, receives COVID-19 vaccine U.S. Air Force Staff Sgt. Kelvin Thomas, 316th Medical Squadron noncommissioned officer in charge of immunizations, administers the Moderna COVID-19 vaccination to U.S. Air Force Lt. General Dorothy A. Hogg, U.S. Air Force and U.S. Space Force Surgeon General, at Joint Base Anacostia-Bolling,